Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-80948543 + JNJ-75348780 in R/R B-Cell NHL
NCT06660563Phase 1Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2024
- Primary completion
- Jan 2026
- Modality
- IgG Antibodies, Trispecific Antibodies
- Countries
- 4
01
Overview
Phase 1, open-label, single-arm trial of JNJ-80948543 in non-Hodgkin lymphoma (NHL), sponsored by Janssen Pharmaceutical. Primary endpoints: Dose-limiting Toxicity and Adverse Events. Started Oct 2024; status: active, not recruiting.
02
Drugs
JNJ-80948543
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT06660563.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06660563.